Tag: FRα
Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer
Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...
Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...
MORAb-202 has Potential Anti-tumor Effects in Breast Cancer
MORAb-202, Eisai’s first antibody-drug conjugate, targets FRα-positive solid tumors. The investigational agent is composed of the company’s in-house developed anticancer agent farletuzumab, a humanized...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
Companion Diagnostics: Paving the Way for Personalized Medicine
There has been a real revolution in the understanding of molecular biology. This revolution is fueled by the rapid decline in the costs of...
